My ePortfolio Register   

ESMO 2017 /
LORELEI trial of letrozole and taselisib for ER positive breast cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 575
Rating:

Dr Cristina Saura - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Saura speaks with ecancer at ESMO 2017 about the results of the LORELEI trial, in which women with ER positive, HER2 negative advanced breast cancer were treated with a combination of letrozole and taselisib.

Dr Saura describes the pathways and intended action of targeting PI3K, and how these results are leading into a phase III trial called SANDPIPER, which was discussed further at WIN 2017 in Paris

These results are also discussed by Prof Miguel Martin in his summary of breast cancer news from ESMO.

Read more about the results here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence